In this article
SAMD9 and SAMD9L Mutations in Familial MDS and AML
Researchers at the University of California, San Francisco and St. Jude Children ’s Research Hospital in Tennessee have solved medical mysteries decades ago, and they have discovered a pair of genetic mutations that may cause familial blood diseases and even leukemia. This study is based on DNA analysis of 16 siblings in 5 families, pointing out that some children with inherited mutations will recover on their own, and also found some other genetic markers that help doctors avoid invasive and dangerous bone marrow transplants.
The problems surrounding this disease can be traced back more than 30 years ago, when the oncologist Kevin Shannon, MD, of the University of California, San Francisco, and colleagues met several families, many of whom may have low blood cell counts (abnormal myelodysplastic syndrome) Sign or MDS) and an acute myeloid leukemia (AML), a severe and fatal blood cancer. These patients have one instead of the usual two copies of chromosome 7, which is called single chromosome 7.
Monosomy 7 Impact on Leukemia Prognosis
The data shows that mutations in the genes SAMD9 and SAMD9L located on chromosome 7 are closely related to single chromosome 7 syndrome, but many healthy siblings and patients’ parents also carry these mutations without any symptoms. Researchers have shown that patients who do have symptoms of MDS and AML also have a specific secondary gene mutation, which can drive a more serious disease, and patients without these additional mutations often never experience any symptoms and may develop blood. The count is low but most can recover on their own without treatment.
Genetic changes on chromosome 7 are very frequent in patients with AML and MDS, and malignant tumors of single chromosome 7 are associated with poor prognosis and do not respond well to existing therapies. With more than 860 genes on chromosome 7, it will be interesting to understand the role of SAMD9 and SAMD99L in non-familial MDS and AML and how they interact with other genes on chromosome 7.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Susan Hau
Susan Hau is a distinguished researcher in the field of cancer cell therapy, with a particular focus on T cell-based approaches and cancer vaccines. Her work spans several innovative treatment modalities, including CAR T-cell therapy, TIL (Tumor-Infiltrating Lymphocyte) therapy, and NK (Natural Killer) cell therapy. Hau's expertise lies in cancer cell biolo…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.